Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Non-Current Liabilities: 2021-2024

Historic Other Non-Current Liabilities for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $426,000.

  • Autolus Therapeutics' Other Non-Current Liabilities rose 5.59% to $472,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $472,000, marking a year-over-year increase of 5.59%. This contributed to the annual value of $426,000 for FY2024, which is 19.33% up from last year.
  • Autolus Therapeutics' Other Non-Current Liabilities amounted to $426,000 in FY2024, which was up 19.33% from $357,000 recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Other Non-Current Liabilities registered a high of $426,000 during FY2024, and its lowest value of $116,000 during FY2022.
  • Over the past 3 years, Autolus Therapeutics' median Other Non-Current Liabilities value was $357,000 (recorded in 2023), while the average stood at $299,667.
  • Per our database at Business Quant, Autolus Therapeutics' Other Non-Current Liabilities dropped by 9.38% in 2022 and then soared by 207.76% in 2023.
  • Over the past 4 years, Autolus Therapeutics' Other Non-Current Liabilities (Yearly) stood at $128,000 in 2021, then declined by 9.38% to $116,000 in 2022, then surged by 207.76% to $357,000 in 2023, then climbed by 19.33% to $426,000 in 2024.